CHARTER COMMUNITY HOSPITAL
1818 48th Street
Des Moines, Iowa 50310
(515) 271-6000

July 18, 1985

U.S. Nuclear Regulatory Commission
Materials Licensing Section, Region III
799 Roosevelt Road, Bldg 4
Glen Ellyn, Illinois 60137

Gentlemen:

Please consider this letter to be an application to amend license number 14-17836-01, issued to Charter Community Hospital, 1818 48th, Des Moines, Ia. as follows:

1. To add Xenon-133 in the physical form of gas or gas in solution in a maximum amount of 200 mCi.

2. To add Gadolinium-153 as a sealed source to be used in a Lunar DP3 dual photon bone densitometry device in the amount of 1.3 Curies with the maximum on site 1.5 Curies.

3. The addition of Stephan M. Cooper, M.D. as an authorized user. Dr. Cooper is currently listed as an authorized user on license number 14-01137-01, copy of which is enclosed.

Please find enclosed a check for $120 to cover the amendment fee for Catagory 7B of materials licensing.

Sincerely,

David G. Triebes
Administrator

Applicant Chy 3 III
Check No. 005882
Amount Fee Category $120
Type of Fee 7C and E
Date Check Rec'd 7/1/85
Received By

RECEIVED
JUL 25 1985
REGION III

8509110418 850827
REG3 LIC30
14-17836-01 PDR

JUL 25 1985

CONTROL NO. 79410

CHARTER COMMUNITY HOSPITAL OF DES MOINES
1818 [illegible] STREET
DES MOINES, IOWA 50310

NO. 0005820

DATE 7-19-85

INVOICE/CONTRACT	INVOICE DATE	DESCRIPTION	VOUCHER NO.	GROSS AMOUNT	DISCOUNT AMT.	NET AMOUNT
	7-19-85	NRC License Ameddments				
DETACH AND RETAIN THIS STATEMENT THE ATTACHED CHECK IS IN PAYMENT OF ITEMS DESCRIBED ABOVE NOT CORRECT PLEASE NOTIFY US PROMPTLY. NO RECEIPT REQUIRED.			TOTALS ▶			

CHARTER COMMUNITY HOSPITAL OF DES MOINES
1818 48th STREET
DES MOINES, IOWA 50310

2808 North Avenue, Grand Junction, Colorado 81501
Mesa United Bank of Grand Junction
National Association

82-91/1021

No.0005820
CONTROL NO.

WELLS FARGO BANK, N.A.

INVOICE OR CONTRACT NO.

DATE 7-19-85

PAY EXACTLY **********$120. DOLLARS 00 CENTS

PAY EXACTLY$********120.00

U. S. Nuclear Regulatory Comm.

NOT NEGOTIABLE

⑈0058 20⑈ ⑆102100918⑆ 001 3768⑈

This is a copy of a check that was mailed under separate cover.

NRC Form 374
(5-84)

U.S. NUCLEAR REGULATORY COMMISSION

CORRECTED COPY

MATERIALS LICENSE

Amendment No. 52

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93 - 438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. Mercy Hospital Medical Center Administrative Director Radiology Department 2. Sixth and University Des Moines, IA 50314	In accordance with application dated February 1, 1985 3. License number 14-01137-01 is amended in its entirety to read as follows:
	4. Expiration date: June 30, 1990
	5. Docket or Reference No.: 030-01683

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. Any radiopharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. As necessary for uses authorized in Subitem 9.A
B. Any byproduct material listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. Any form listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. 3 curies of each byproduct material authorized in Subitem 6.B
C. Any byproduct material listed in Section 31.11(a) of 10 CFR 31	C. Prepackaged kits	C. 3 millicuries of each byproduct material authorized in Subitem 6.C
D. Iodine-131	D. Any iodide that has been manufactured, labeled, packaged, and distributed in accordance with a specific license issued pursuant to Section 32.72 of 10 CFR Part 32 of a specific license issued to a manufacturer by an Agreement State pursuant to equivalent State regulations	D. 200 millicuries
E. Iodine-125	E. Sealed source(s) (AECL Model C-324 enclosed within source holder AECL Model C-236)	E. 2 sources not to exceed 200 millicuries each

8506250338 1pp

COPY 5

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 14-01137-01

Docket or Reference number: 030-01683

CORRECTED COPY

Amendment No. 52

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
F. Xenon-133	F. Gas or gas in solution that is the subject of an active (i.e., not withdrawn or terminated) "New Drug Application" (NDA) approved by FDA or an active (i.e., not withdrawn, terminated or on "clinical hold" "Notice of Claimed Investigational Exemption for a New Drug" (IND) that has been accepted by FDA	F. 600 millicuries

9. Authorized Use

A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

C. In vitro studies.

D. For treatment of hyperthyroidism, cardiac dysfunction or thyroid carcinoma.

E. One source to be used in a Nuclear Data Model 1100 Bone Densitometer Scanner for bone mineral analysis on humans. One source in its shipping container to be in possession of the licensee as necessary to the replacement of the source holder AECL Model C-236 in the Nuclear Data Model 1100 Bone Densitometer Scanner.

F. Blood flow studies. Pulmonary function studies.

CONDITIONS

10. Licensed material shall be used at Mercy Hospital, Sixth and University, Des Moines, Iowa. Licensed material for diagnosis except for xenon-133 may also be used at any hospital located in the State of Iowa provided: (a) The hospital does not have a byproduct material license under Section 35.11 of 10 CFR Part 35, (b) The licensee has the prior written permission from the hospital's administrator, (c) The licensee performs a daily contamination survey in all areas where radioactive materials are used, (d) The licensee removes all byproduct material when he departs other than the amount remaining in the patient, and (e) The licensee maintains a list of all hospital's serviced in the State of Iowa in any calendar year and submits the list to the Nuclear Regulatory Commission, Region III, Office of Inspection and Enforcement, 799 Roosevelt Road, Glen Ellyn, Illinois 60137, by March 1, of each year. The Nuclear Data 1100 Bone Densitometer Scanner shall be used at Mercy Medical Plaza, 421 Laurel Street, Suite 410, Des Moines, Iowa.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 14-01137-01

Docket or Reference number: 030-01683

CORRECTED COPY

Amendment No. 52

11. The licensee shall comply with the provisions of Title 10, Chapter 1, Code of Federal Regulations, Part 19, "Notices, Instructions and Reports to Workers; Inspections" and Part 20, "Standards for Protection Against Radiation."

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

Julio Acebey, M.D.	Groups I, II and III Xenon-133 Iodine-125 for use in a bone densitometer scanner
Harrison W. Pratt, D.O.	Group I In vitro studies Iodine-125 for use in a bone densitometer scanner
Stephan M. Cooper, M.D.	Groups I, II and III Iodine-131 for treatment of hyperthyroidism, cardiac dysfunction or thyroid carcinoma Xenon-133 In vitro studies Iodine-125 for use in a bone densitometer scanner
John Henderson, M.D.	Groups I, II and III Iodine-131 for treatment of hyperthyroidism, cardiac dysfunction or thyroid carcinoma Xenon-133 Iodine-125 for use in a bone densitometer scanner
Michael A. Disbro, M.D.	Groups I, II and III Iodine-131 for treatment of hyperthyroidism, cardiac dysfunction or thyroid carcinoma Xenon-133 Iodine-125 for use in a bone densitometer scanner

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 14-01137-01

Docket or Reference number: 030-01683

CORRECTED COPY

Amendment No. 52

13. For a period not to exceed sixty (60) days in any calendar year, a visiting physician is authorized to use licensed material for human use under the terms of this license, provided the visiting physician:

(a) Has the prior written permission of the hospital's Administrator and its Medical Isotopes Committee, and

(b) Is specifically named as a user on a Nuclear Regulatory Commission license authorizing human use, and

(c) Performs only those procedures for which he is specifically authorized by a Nuclear Regulatory Commission license.

The licensee shall maintain for inspection by the Commission, copies of the written permission specified in Subitem (a) above and of the license(s) specified in Subitems (b) and (c) above. These records shall be maintained for five (5) years from the time the licensee grants its permission under Subitem (a) above.

14. Licensed material shall be used in accordance with the provisions of Section 35.14(b)(c)(e) and (f) of Title 10, Code of Federal Regulations.

15. The licensee may use the Calichek device for doing linearity tests of his dose calibrator provided he follows the procedures in the Calcorp, Inc., Manual dated March 2, 1982.

16. The licensee may use the Lineator device for doing linearity tests of his dose calibrator provided he follows the procedures in the Atomic Products Corporation Lineator Instructions Manual dated June 20, 1983.

17. The licensee may transport licensed material or deliver licensed material to a carrier for transport in accordance with the provisions of Title 10, Code of Federal Regulations, Part 71, "Packaging of Radioactive Material for Transport and Transportation of Radioactive Material Under Certain Conditions."

18. Patients containing Iodine 131 for the treatment of thyroid carcinoma (or patients containing therapeutic quantities of Gold 198) shall remain hospitalized until the residual activity is 30 millicuries or less.

19. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application dated February 1, 1985; and letters dated December 26, 1984 and April 5, 1985. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

For the U.S. Nuclear Regulatory Commission

Date June 7, 1985

Original Signed By
John R. Madera
Materials Licensing Section, Region III

CONTROL NO. 7 9410 COPY